nasdaq:xoma
|
12673
|
Apr 14th, 2024 12:00AM
|
XOMA
|
4.7K
|
125.00
|
Open
|
|
Apr 13th, 2024 11:55PM
|
Apr 13th, 2024 11:55PM
|
XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of royalty and milestone assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.
All references to “portfolio” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates in XOMA’s posts strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.
|
Open
|
Biotechnology, Pharmaceutical, Licensing, Royalty Aggregator, Royalty Acquirer, and Biotech Deals
|
Open
|
2200 Powell Street
|
Emeryville
|
California
|
US
|
94608
|
|
XOMA
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:xoma
|
12673
|
Apr 13th, 2024 12:00AM
|
XOMA
|
4.7K
|
125.00
|
Open
|
|
Apr 12th, 2024 11:47PM
|
Apr 13th, 2024 12:20PM
|
XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of royalty and milestone assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.
All references to “portfolio” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates in XOMA’s posts strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.
|
Open
|
Biotechnology, Pharmaceutical, Licensing, Royalty Aggregator, Royalty Acquirer, and Biotech Deals
|
Open
|
2200 Powell Street
|
Emeryville
|
California
|
US
|
94608
|
|
XOMA
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:xoma
|
12673
|
Apr 12th, 2024 12:00AM
|
XOMA
|
4.7K
|
125.00
|
Open
|
|
Apr 11th, 2024 11:54PM
|
Apr 12th, 2024 09:16AM
|
XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of royalty and milestone assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.
All references to “portfolio” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates in XOMA’s posts strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.
|
Open
|
Biotechnology, Pharmaceutical, Licensing, Royalty Aggregator, Royalty Acquirer, and Biotech Deals
|
Open
|
2200 Powell Street
|
Emeryville
|
California
|
US
|
94608
|
|
XOMA
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:xoma
|
12673
|
Apr 11th, 2024 12:00AM
|
XOMA
|
4.7K
|
125.00
|
Open
|
|
Apr 11th, 2024 12:50AM
|
Apr 11th, 2024 12:01PM
|
XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of royalty and milestone assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.
All references to “portfolio” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates in XOMA’s posts strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.
|
Open
|
Biotechnology, Pharmaceutical, Licensing, Royalty Aggregator, Royalty Acquirer, and Biotech Deals
|
Open
|
2200 Powell Street
|
Emeryville
|
California
|
US
|
94608
|
|
XOMA
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:xoma
|
12673
|
Apr 10th, 2024 12:00AM
|
XOMA
|
4.7K
|
125.00
|
Open
|
|
Apr 9th, 2024 11:55PM
|
Apr 10th, 2024 06:08PM
|
XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of royalty and milestone assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.
All references to “portfolio” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates in XOMA’s posts strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.
|
Open
|
Biotechnology, Pharmaceutical, Licensing, Royalty Aggregator, Royalty Acquirer, and Biotech Deals
|
Open
|
2200 Powell Street
|
Emeryville
|
California
|
US
|
94608
|
|
XOMA
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:xoma
|
12673
|
Apr 9th, 2024 12:00AM
|
XOMA
|
4.7K
|
125.00
|
Open
|
|
Apr 9th, 2024 12:06AM
|
Apr 9th, 2024 10:50AM
|
XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of royalty and milestone assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.
All references to “portfolio” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates in XOMA’s posts strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.
|
Open
|
Biotechnology, Pharmaceutical, Licensing, Royalty Aggregator, Royalty Acquirer, and Biotech Deals
|
Open
|
2200 Powell Street
|
Emeryville
|
California
|
US
|
94608
|
|
XOMA
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:xoma
|
12673
|
Apr 8th, 2024 12:00AM
|
XOMA
|
4.7K
|
125.00
|
Open
|
|
Apr 8th, 2024 12:58AM
|
Apr 8th, 2024 07:47PM
|
XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of royalty and milestone assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.
All references to “portfolio” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates in XOMA’s posts strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.
|
Open
|
Biotechnology, Pharmaceutical, Licensing, Royalty Aggregator, Royalty Acquirer, and Biotech Deals
|
Open
|
2200 Powell Street
|
Emeryville
|
California
|
US
|
94608
|
|
XOMA
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:xoma
|
12673
|
Apr 7th, 2024 12:00AM
|
XOMA
|
4.7K
|
125.00
|
Open
|
|
Apr 7th, 2024 12:00AM
|
Apr 7th, 2024 12:00AM
|
XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of royalty and milestone assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.
All references to “portfolio” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates in XOMA’s posts strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.
|
Open
|
Biotechnology, Pharmaceutical, Licensing, Royalty Aggregator, Royalty Acquirer, and Biotech Deals
|
Open
|
2200 Powell Street
|
Emeryville
|
California
|
US
|
94608
|
|
XOMA
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:xoma
|
12673
|
Apr 6th, 2024 12:00AM
|
XOMA
|
4.7K
|
124.00
|
Open
|
|
Apr 6th, 2024 12:00AM
|
Apr 6th, 2024 12:00AM
|
XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of royalty and milestone assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.
All references to “portfolio” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates in XOMA’s posts strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.
|
Open
|
Biotechnology, Pharmaceutical, Licensing, Royalty Aggregator, Royalty Acquirer, and Biotech Deals
|
Open
|
2200 Powell Street
|
Emeryville
|
California
|
US
|
94608
|
|
XOMA
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:xoma
|
12673
|
Apr 5th, 2024 12:00AM
|
XOMA
|
4.7K
|
124.00
|
Open
|
|
Apr 5th, 2024 01:09AM
|
Apr 5th, 2024 01:09AM
|
XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of royalty and milestone assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.
All references to “portfolio” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates in XOMA’s posts strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.
|
Open
|
Biotechnology, Pharmaceutical, Licensing, Royalty Aggregator, Royalty Acquirer, and Biotech Deals
|
Open
|
2200 Powell Street
|
Emeryville
|
California
|
US
|
94608
|
|
XOMA
|
Health Care
|
Pharmaceuticals & Biotechnology
|